TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6393316
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg daily intravenously for 2 days, then 1000 mg daily orally for 10 days in divided doses)
Study: 28214596
Drug: certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: certolizumab pegol (400 mg qd reduced to 200 mg qd after one month)
Study: 24823623
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine (ZV; Zostavax; Merck)
Study: 22901348
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg/d, increased to a maximum of 120 mg/d)
Study: 18541798
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of sucrose 40 minutes before exercise
Study: 18541798
Drug: 37 g
Normalized name: BENZALKONIUM CHLORIDE 0.37 g in 100 g TOPICAL LIQUID [YOOLOGY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37 g of sucrose 5 minutes before exercise
Study: 2186237
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (30 mg of prednisone or greater)
Study: 21876310
Drug: Cloxacillin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin (100 mg/mL) plus heparin (1000 IU/mL) as a 2.5-mL solution instilled in each catheter lumen after dialysis session
Study: 10344062
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg
Study: 8110556
Drug: Transdermal hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal hyoscine (loading dose 140 micrograms, followed by 5 micrograms h‐1)
Study: 24330906
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) delivered at 1-3 mA current intensity for 20-30 minutes in once- to twice-daily sessions for up to 3 years
Study: 19423455
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus low molecular weight heparin (LMWH) treatment (LT group, n = 135)
Study: 7831140
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg oral midazolam
Study: 3365924
Drug: Controlled-release intravenous
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release intravenous infusion system (CRIS) with 20 mL of D5NS as the diluent
Study: 3365924
Drug: Controlled-release intravenous
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release intravenous infusion system (CRIS) with 10 mL of 5% dextrose and 0.9% sodium chloride injection (D5NS)
Study: 30100096
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy for low back pain with or without manual therapy and exercise directed at the femoroacetabular joints
Study: 30100096
Drug: Having a
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Having a concurrent hip problem
Study: 26959198
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg, n=615)
Study: 20859299
Drug: Tocotrienol-rich fraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol-rich fraction (TRF) 400 mg daily
Study: 18060999
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment for atrial fibrillation
Study: 8080680
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cyclophosphamide, doxorubicin, 5‐fluorouracil)
Study: 2925456
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g, intravenous administration, 30 to 60 minutes preoperatively)
Study: 26192876
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard recombinant FSH/GnRH antagonist protocol)
Study: 15611423
Drug: Oral PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PUVA using methoxsalen capsules and a portable tanning unit at home
Study: 31300493
Drug: NRT patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT patches
Study: 27795779
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% (1 ml/kg) with fentanyl 1 μg/kg and clonidine 1μg/kg (group I)
Study: 27795779
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% (1 ml/kg) with fentanyl 1 μg/kg (group II)
Study: 20723260
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg
Study: 9410299
Drug: Budesonide (Pulmicort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (Pulmicort and Horacort) 640 mg or 800 mg daily for 6 weeks
Study: 8408569
Drug: High-titer vaccine
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer vaccine (10^6 PFU)
Study: 8408569
Drug: Low-titer vaccine
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-titer vaccine (10^5 PFU)
Study: 31353941
Drug: Scapular exercise
Normalized name: Haemophilus capsular oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scapular exercise programme plus physical therapy treatment
Study: 26704923
Drug: 80 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg/day Vitamin D3 dissolved in oil
Study: 21663811
Drug: GlideScope (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlideScope (G)
Study: 2344752
Drug: Kinetic Treatment
Normalized name: Kineticream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic Treatment Table (KTT)
Study: 6108449
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aminoacid therapy)
Study: 17288990
Drug: Narrative Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Exposure Therapy (NET), 5 sessions
Study: 9433650
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of grepafloxacin (200 to 1200 mg)
Study: 9433650
Drug: Repeat oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat oral administration of grepafloxacin (400 and 800 mg)
Study: 3786346
Drug: Nicotine chewing
Normalized name: nicotine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine chewing gum (2 mg)
Study: 27933408
Drug: PRO +
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRO + PRT (0.33 g/kg body mass of a milk-based protein matrix for 12 weeks)
Study: 27933408
Drug: PRO (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO (0.33 g/kg body mass of a milk-based protein matrix for 12 weeks)
Study: 21226674
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy group
Study: 15002680
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to mental health treatment
Study: 15002680
Drug: Referral rates
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral rates to substance abuse and mental health treatment
Study: 3234475
Drug: Alcoholic oral
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic oral solution (12 mg)
Study: 3234475
Drug: Tablets (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (12 mg)
Study: 28038865
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg administered ∼24 hours after chemotherapy plus bevacizumab every 14 days for 4 cycles, with the option to continue for ≤ 60 months)
Study: 28038865
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered ∼24 hours after chemotherapy plus bevacizumab every 14 days for 4 cycles, with the option to continue for ≤ 60 months)
Study: 23907740
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg IV over 1 hour q12h for ABSSSI and CABP patients
Study: 23907740
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 50-2000 mg IV infusion over 1 hour or IM injection q12h or q24h for healthy subjects
Study: 19860230
Drug: Propofol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.75 mg x kg(‐1)) and Suxamethonium (1.2 mg x kg(‐1))
Study: 15583914
Drug: SPECT measurements
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT measurements of dopamine D2-like receptors (D2) using 123I‐epidepride in patients
Study: 9211474
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg proglumide
Study: 9211474
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg proglumide
Study: 9211474
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg proglumide
Study: 2970220
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 physicians received general information about vaccine decisions; specific outcome not detailed.
Study: 14714360
Drug: Tripterygium polyglycosides
Normalized name: Tripterygium wilfordii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium polyglycosides tablet and composite Salviae tablet (Control)
Study: 2048660
Drug: Intravenous diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diamorphine 0.5 mg/hour as a supplement to extradural bupivacaine (0.125% at 15 ml/hour)
Study: 2048660
Drug: Extradural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural diamorphine 0.5 mg/hour as a supplement to extradural bupivacaine (0.125% at 15 ml/hour)
Study: 9125
Drug: Atropine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.6 mg
Study: 7272153
Drug: Glycopyrrolate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.3 mg or 0.2 mg
Study: 15681941
Drug: 5-ml saline
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ml saline injection
Study: 15681941
Drug: 10-ml saline
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-ml saline injection
Study: 15681941
Drug: 15-ml saline
Normalized name: FENTANYL 2MCG/ROPIV 0.15%/ML NS 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-ml saline injection
Study: 15681941
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no saline injection)
Study: 2906171
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice daily for 7 days
Study: 1817630
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of pancuronium (10 micrograms kg‐1)
Study: 6127172
Drug: Acebutolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (1 mg/kg i.v. during the first 2 days followed by a daily oral dose of 600 mg for 3 weeks)
Study: 28385440
Drug: Implant-retained fixed
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained fixed metal-acrylic resin prostheses
Study: 9650870
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy plus scaling (group 2)
Study: 9650870
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy plus scaling (group 4)
Study: 9650870
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy but no scaling (group 3)
Study: 9650870
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of metronidazole plus amoxicillin
Study: 2651328
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg) alone
Study: 2651328
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg) and nifedipine (20 mg)
Study: 2651328
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg) and nicardipine (40 mg)
Study: 406634
Drug: Methadone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (up to 10 mg)
Study: 15485290
Drug: 12-dose WHO
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-dose WHO multi-drug therapy (Group 1, 128 patients)
Study: 15485290
Drug: 24-dose WHO
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-dose WHO multi-drug therapy (Group 2, 85 patients)
Study: 4020569
Drug: Cholestyramine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 2 g four times daily
Study: 7818005
Drug: Ursodiol 600
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol 600 mg
Study: 31429974
Drug: 8-week smartphone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week smartphone-based aftercare intervention (German version of 'Recovery Record') with therapist feedback as an adjunct to treatment as usual
Study: 22229712
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg meperidine in 10 mL of saline (slow intravenous injection over 2 min)
Study: 22229712
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of isotonic saline (control group)
Study: 2239141
Drug: ACTH treatment
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH treatment (100 units intramuscular, tapered over 12 weeks)
Study: 26486190
Drug: Postmenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal hormone therapy (0.625 mg/day conjugated equine estrogens with or without 2.5 mg/day medroxyprogesterone acetate)
Study: 20080928
Drug: Bupropion sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion sustained release 150 mg b.i.d. (n = 109)
Study: 19207322
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel with preincorporated lidocaine
Study: 10193975
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg twice daily
Study: 15018852
Drug: Famciclovir 250
Normalized name: famciclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 250 mg three times daily
Study: 15018852
Drug: Aciclovir 800
Normalized name: Aciclovir 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 800 mg five times daily
Study: 319816
Drug: Naloxone 0.1
Normalized name: naloxone 0.18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.1 mg
Study: 319816
Drug: Naloxone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.2 mg
Study: 11297596
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg/day)
Study: 29496722
Drug: Calcium +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium + Vitamin D (1200 mg/day calcium and 1000 IU/day vitamin D3)
Study: 14744472
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) 20 mg/day
Study: 14744472
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FLX 20 mg/day and DMI
Study: 1474165
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 200 mg oral dose during interdialytic period
Study: 1474165
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 200 mg oral dose during intradialytic period
Study: 15899952
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at doses ranging from 0.18-0.37 mg/kg.wk
Study: 6231863
Drug: Dilute sulfuric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute sulfuric acid containing sodium sulfate (solution A)
Study: 19948449
Drug: Interval debulking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval debulking surgery after neo-adjuvant chemotherapy
Study: 2412069
Drug: Ketanserin treatment
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin treatment for 9 months
Study: 8247951
Drug: Ketanserin therapy
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin therapy
Study: 7595712
Drug: Cisplatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (20 mg/m2) plus Etoposide (100 mg/m2) (VP)
Study: 7595712
Drug: Cisplatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (20 mg/m2), Ifosfamide (1.2 g/m2), and Etoposide (75 mg/m2) (VIP)
Study: 2135137
Drug: GaAlAs laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAlAs laser diode treatment (active group)
Study: 27956455
Drug: Annual oral
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual oral azithromycin treatment of the entire community
Study: 21829748
Drug: rDEN1Δ30 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rDEN1Δ30 vaccine (2 doses, subcutaneous)
Study: 9572698
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream 5% (n = 64)
Study: 7972311
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 ml at 0, 2, 4, 8 and 12 h)
Study: 26133944
Drug: HA +
Normalized name: PNV-DHA + Docusate Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA + CS injection
Study: 15933223
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (0.5-mL intramuscular dose)
Study: 15933223
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine (Td)
Study: 12534409
Drug: Baclofen 40
Normalized name: baclofen 40,000 MCG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 40 mg p.o.
Study: 2903059
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine
Study: 1678220
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg terfenadine
Study: 6781588
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with minimal bandage
Study: 28578210
Drug: Vaccine refusal
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine refusal vignette
Study: 28578210
Drug: Vaccine delay
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine delay vignette
Study: 14990647
Drug: CCI-779 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCI-779 (25, 75, or 250 mg weekly as a 30-minute intravenous infusion)
Study: 9184576
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immune globulin infusions (2 g/kg)
Study: 29781043
Drug: 4 day
Normalized name: Ponvory 14 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 day course of antibiotics (Group 1)
Study: 29781043
Drug: 7 day
Normalized name: ZonaCort 7 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day course of antibiotics (Group 2)
Study: 12817155
Drug: Citalopram (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20-40 mg/day)
Study: 7937278
Drug: Aconiazide tablets
Normalized name: Aconiazide
DrugBank: Aconiazide (DB17731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aconiazide tablets 650 mg (containing isoniazid 300 mg)
Study: 16175328
Drug: 2 percent
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL GEL [The Keeps ETHANOL 62 percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 percent diltiazem ointment
Study: 11337622
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with early mobilization using a hyperextension brace (n = 47)
Study: 20350955
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 or 15 mg
Study: 8249562
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml epidural blood patch (EBP)
Study: 8249562
Drug: 10-15 ml
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 ml epidural blood patch (EBP)
Study: 8249562
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml and 10-15 ml epidural blood patch (EBP)
Study: 29870578
Drug: GSK2330672 (10-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 (10-180 mg)
Study: 23635914
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 to 1.5 mg) intravenously
Study: 19277410
Drug: DAWN AC
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAWN AC computer-assisted dosage program
Study: 18317605
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive with estriol (group 2)
Study: 18317605
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive without estriol (group 1)